Clinical implications of polymers and lipids in designing drug delivery systems in geriatric use

Sai Raj Kappari
Chief Program Officer and Co-founder of HEMA, Inc., USA.

ABSTRACT
This paper will emphasize some of the clinical implications of polymers and lipids in designing drug delivery systems in the geriatric population. This article will give us an overview of the advantages and disadvantages of polymers and lipids in formulating DDS in individuals over 65 in the United States. Lipid polymer hybrids can be advantageous in systemic drug bioavailability to patients who have decreased drug carrier capacity. Older adults may benefit from lipid polymer hybrids as it enhances drug delivery and drug targeting process. Most of the older adults use a minimum of 4 to 6 medications for a variety of medical ailments and conditions. Polypharmacy may be an advent situation in some of the cases, which can be reduced by innovative drug delivery options.

Keywords: Geriatrics, Lipids, Polymers, Drug delivery, Polymer hybrids, Polypharmacy, Drug carrying capacity.

INTRODUCTION
In the United States, the population age 65 and over numbered over 56.4 million in 2020 (estimated for which data are available) and represents 16% of the total population [1]. The average life expectancy of individuals has increased over the decades and it is 78.9 years. Women tend to outlive men over 4 years on average [2]. Older adults have a minimum of one chronic condition and many have multiple chronic conditions (Shah et al., 2017) [3,4]. The top five chronic ailments were hypertension (58%), hyperlipidemia (47%), arthritis (30%), Ischemic Heart Disease (28%), and diabetes (26%) [5]. Individuals on average take 4 to 6 medications daily and have seen by a doctor two to three times a year. Older adults tend to take vaccinations more than the general population especially the pneumococcal (70%) and influenza (73%) [6,7]. More than 30% of individuals over 65 are obese. Physical activity is followed by close to half of the individuals in 65 to 74 age groups and only 26% of people over 75 engage in any physical activity [8,9]. Older adults average more office visits with a doctor or other health care professionals than young individuals [10]. People who are over 75 about 25% have 10 or more visits to a doctor in a year. The majority of individuals over 65 have Medicare or Medicaid insurance [11,12]. Body metabolism decreases as we age and an individual’s regular physiological activities decrease which affects all the organ systems [13,14]. A series of functionalities are lost in tissue and cellular levels as individual age [15,16,17].

Trends in the use of polymers and lipids in drug delivery systems for geriatrics
Lipid and Polymer hybrids may improve the drug bioavailability in the vulnerable population due to a decrease in the body's physiological activities (Lasic, 2001) [18,19]. The release of drug to a systemic site can increase the drug activity that can decrease the drug side effect impact on the individuals with decreasing glomerular filtration rate [20,21]. As individuals age the GFR reduces through age and the condition can be considered normal for higher age even the rate is 30 ml/min (Glassock & Winears, 2009) [22,23]. Targeted drug release can lower the risk of drug-food and drug-drug interaction [24]. Oral administration of medications may be less effective as the gastric activity is reduced with age. Polypharmacy can be minimized when drugs are taken through a special mode of administration improving the therapeutic index while reducing side effects. Successfully targeting specific cells for the release of the payload of drugs.
can benefit older adults at a higher rate than the regular means of medication administration [25, 26].

These lipid-polymer hybrids are prominent in building confidence in the modern approach to improving the health and wellbeing of individuals [27, 28, 29]. These hybrids are beneficial for the enhancement of oral absorption and bioavailability, targeting delivery systems, effectively increasing biological membrane permeability, on-site release, and overcoming the polypharmacy aspect of multiple drug resistance in the older adult population [30, 31, 32].

Clinical implications by using lipid/polymer-based delivery systems for geriatrics

Older adults are easily susceptible to disease conditions especially infections that are caused due to reduced immune response [33, 34, 35]. There are inadequate evidence and knowledge about how geriatric patients respond to liposome-polymer hybrid and the effectiveness of any medication at large given the overall condition of the physiology of an older adult, most clinical trials omit testing individuals over 65 (Fahy et al., 2011) [36, 37, 38, 39, 40].

Geriatric individuals can respond differently than the younger generations to drug targeted therapy [41, 42, 43]. Pharmacokinetics and Pharmacodynamics are affected due to age-related physiological changes, which are inevitable as reversing age is not possible [44, 45, 46]. Older adults are at a higher risk to develop adverse effects due to concomitant drugs and comorbidities (Clark, 2015) [47, 48, 49]. Nanoparticles such as the lipid polymer hybrids may deplete or reduce pulmonary function, as they are easily permeable into the human body and carried across by systemic circulation [50, 51]. The mode of administration of drug and therapeutic index plays a pivotal role in bringing a focused approach to the therapy of a particular ailment [52, 53], and it may or may not be successful in an individual with comorbid conditions and most of the older adults have these conditions (Bartlam, Lally and Crome, 2010) [54, 55, 56]. These lipid-polymer hybrids may benefit individuals who have an earlier diagnosis of any form of cancer or life-sustaining conditions, provided the benefit does not overtake the risk (Hutchins, 1999) [57, 58, 59, 60].

CONCLUSION

In conclusion, lipid-polymer hybrids are some most sophisticated approaches in drug delivery systems [61, 62, 63], which can enhance and improve the quality of therapeutic advancements in treating geriatric patients [64, 65, 66]. The procedural conduct may increase over time with enhancements in modern therapies. Most of the clinical studies are conducted on the individual with an inclusion criterion between 18 to 64 years [67, 68, 69]. In recommendation we can educate older adults on the importance of being part of these studies in creating novel models for all generations [70, 71].

REFERENCES

1. Allen, T. M. (1997). Liposomes. Drugs, 54(4), 8-14.
2. Lally, F., & Crome, P. (2010). The PREDICT study: increasing the participation of the elderly in clinical trials: the opinions of medical and associated professionals. Keele University: Accessed.
3. Clark, M. (2015). Prediction of clinical risks by analysis of preclinical and clinical adverse events. Journal of Biomedical Informatics, 54, 167-173.
4. Fahy, N., McKee, M., Busse, R., & Grundy, E. (2011). How to meet the challenge of ageing populations.
5. Glassock, R. J., & Winearls, C. (2009). Ageing and the glomerular filtration rate: truths and consequences. Transactions of the American Clinical and Climatological Association, 120, 419.
6. Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman Jr, C. A., & Albain, K. S. (1999). Underrepresentation of patients 65 years of age or older in cancer treatment trials. New England Journal of Medicine, 341(27), 2061-2067.
7. Lasic DD, Bolotin E, Brey RN. Polymerized liposomes. From biophysics to applications. Part II. Chimica Oggi-Chemistry Today. 2001;19(1–2):45–48.
8. Lewis, J. H., Kilgore, M. L., Goldman, D. P., Trimble, E. L., Kaplan, R., Montello, M. J., ... & Escarce, J. J. (2003). Participation of patients 65 years of age or older in cancer clinical trials. Journal of clinical oncology, 21(7), 1383-1389.
9. Shah K, Villareal DT. Obesity. In: Fillit HM, Rockwood K, Young J, eds. Brocklehurst’s Textbook of Geriatric Medicine. 8th ed. Philadelphia, PA: Elsevier (2017) Chap 80.
10. Levit, L. A., Singh, H., & Klepin, H. D. (2020). Cancer and aging activities at the American Society of Clinical Oncology and beyond: Reflections on the legacy of Dr. Arti Hurria. Journal of geriatric oncology, 11(2), 151-153.
11. Walston, J. D. (2016). Common clinical sequelae of aging. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders.
12. Dahan, A., & Hoffman, A. (2008). Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. Journal of controlled release, 129(1), 1-10.
13. Ahmed, O. A. A., Kurakula, M., Banjar, Z. M., Afouna, M. I., &Zidan, A. S. (2015). Quality by design coupled with near infrared in formulation of transdermal glimepiride liposomal films. Journal of Pharmaceutical Sciences, 104(6), 2062-2075. https://doi.org/10.1002/jps.24448.
14. Kalepu, S., Manthina, M., &Padavala, V. (2013). Oral lipid-based drug delivery systems—an overview. Acta PharmaceuticaSinica B, 3(6), 361-372.
15. Murali, V. P., Fujiwara, T., Gallop, C., Wang, Y., Wilson, J. A., Atwill, M. T., Kurakula, M., & Bumgardner, J. D. (2020). Modified electrospun chitosan membranes for controlled release of simvastatin. International Journal of Pharmaceutics, 584, 119438. https://doi.org/10.1016/j.ijpharm.2020.119438

16. Abdelhady, S., Honisy, K. M., & Kurakula, M. (2015). Electro Spin- Nanofibrous Mats: A Modern Wound Dressing Matrix with a Potential of Drug Delivery and Therapeutics. Journal of Engineered Fibers and Fabrics, 10 (4), 1558925015010000. https://doi.org/10.1177/15589250150100411

17. Chen, J., Ansell, S., Akinc, A., Dorkin, J. R., Qin, X., Cantley, W., ... & Jayaraman, M. (2012). U.S. Patent No. 8,158,601. Washington, DC: U.S. Patent and Trademark Office.

18. Xiao, H., Yan, L., Dempsey, E. M., Song, W., Qi, R., Li, W., ... & Chen, X. (2018). Recent progress in polymer-based platinum drug delivery systems. Progress in Polymer Science, 87, 70-106.

19. Kurakula, M., Mohd, A. B., A. P. R., & Diwan, P. V. (2011a). Estimation of Prednisolone in Proliposomal formulation using RP HPLC method. Int. J. Res. Pharm. Biomed. Sci. 2011; 2: 663, 2(4), 1663–1669.

20. Kurakula, M., Sobahi, T. R., El-Helw, A., & Abdelaal, M. Y. (2014). Development and validation of a RP-HPLC method for assay of atorvastatin and its application in dissolution studies on thermosensitive hydrogel-based nanocrystals. Tropical Journal of Pharmaceutical Research, 13(10), 1681–1687. https://doi.org/10.4314/tjpr.v13i10.16.

21. Kurakula, M., Mohd, A. B., Rao, P. A., & Diwan, P. V. (2011). Estimation of piroxicam in proliposomal formulation using RP-HPLC method. Int. J. Chem. Anal. Sci. 2011; 2: 1193, 1196.

22. Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013). Nanocarriers for delivery of platinum anticancer drugs. Advanced drug delivery reviews, 65(13-14), 1667-1685.

23. Kurakula, M., Srinivas, C., Kasturi, N., & Diwan, P. V. (2012). Formulation and Evaluation of Prednisolone Proliposomal Gel for Effective Topical Pharmacotherapy. International Journal of Pharmaceutical Sciences and Drug Research, 4(1), 35. www.ijpsdr.com.

24. Mallesh, K., Pasula, N., & Kumar Ranjith, C. P. (2012). Piroxicam proliposomal gel: a novel approach for topical delivery. Journal of Pharmacy Research, 5(3), 1755–1763.

25. Min, Y., Mao, C. Q., Chen, S., Ma, G., Wang, J., & Liu, Y. (2012). Combating the drug resistance of cisplatin using a platinum prodrug based delivery system. Angewandte Chemie, 124(27), 6846-6851.

26. Hosny, K. M., Aldawsari, H. M., Bahmdan, R. H., Siddi, A. M., Kurakula, M., Alrobaian, M. M., Aldryhim, A. Y., Alkalhili, H. M., Bahmdan, H. H., Khalaf, R. A., & El Sisi, A. M. (2019). Preparation, Optimization, and Evaluation of Hyaluronic Acid-Based Hydrogel Loaded with Miconazole Self-Nanoemulsion for the Treatment of Oral Thrush. AAPS PharmSciTech, 20(7), 297. https://doi.org/10.1012/512249-019-1496-7

27. Vanitasagar, S., Srinivas, C., Subhashini, N. J. P., & Mallesh, K. (2012). Solid dispersion-a comparative study on the dissolution rate of aceclofenac. International Journal of Pharmacy and Pharmaceutical Sciences, 4(SUPPL.3), 274–278.

28. Venkatesh, M., & Mallesh, K. (2013). Self-nano emulsifying drug delivery system (SNEDDS) for oral delivery of atorvastatin-formation and bioavailability studies. Journal of Drug Delivery and Therapeutics, 3(3), 131-140.

29. Mazzaferro, S., Bouchemal, K., & Ponchel, G. (2013). Oral delivery of anticancer drugs III: formulation using drug delivery systems. Drug discovery today, 18(1-2), 99-104.

30. Developing Lipid-Based Formulations (https://www.pharmtech.com/view/developing-lipid-based-formulations)

31. Mora-Huertas, C. E., Fessi, H., & Elaissari, A. (2010). Polymer-based nanocapsules for drug delivery. International Journal of Pharmaceutics, 385(1-2), 113-142.

32. Raghavendra Naveen, N., Kurakula, M., & Gowthami, B. (2020). Process optimization by response surface methodology for preparation and evaluation of methotrexate loaded chitosan nanoparticles. Materials Today: Proceedings. https://doi.org/10.1016/j.matpr.2020.01.491

33. Shapland, J. E., Hildelbrand, K. R., Racchini, J. R., Shimada, J., & Knudson, M. B. (1998). U.S. Patent No. 5,807,306. Washington, DC: U.S. Patent and Trademark Office.

34. Naguib, Ghada Hussein, Al-Hazmi, F. E., Kurakula, M., Abdulaziz Al-Dharrab, A., Mohamed Hosny, K., Mohammed Alkhalidi, H., Tharwat Hamed, M., Habiballah Hassan, A., Al-Mohammadi, A. M., Mohamed Alnowaiser, A., & Henry Pashley, D. (2018). Zein coated zinc oxide nanoparticles: Fabrication and antimicrobial evaluation as dental aid. International Journal of Pharmacology, 14(8), 1051–1059. https://doi.org/10.3923/ijip.2018.1051.1059
35. Sahatjian, R. (1994). U.S. Patent No. 5,304,121. Washington, DC: U.S. Patent and Trademark Office.

36. Liechty, W. B., Kryscio, D. R., Slaughter, B. V., & Peppas, N. A. (2010). Polymers for drug delivery systems. Annual review of chemical and biomolecular engineering, 1, 149-173.

37. Kurakula, M., Ahmed, O. A. A., Fahmy, U. A., & Ahmed, T. A. (2016). Solid lipid nanoparticles for transdermal delivery of avanafil: optimization, formulation, in-vitro and ex-vivo studies. Journal of Liposome Research, 26(4), 288-296. https://doi.org/10.3109/08982104.2015.1117490

38. Son, G. H., Lee, B. J., & Cho, C. W. (2017). Mechanisms of drug release from advanced drug formulations such as polymeric-based drug delivery systems and lipid nanoparticles. Journal of Pharmaceutical Investigation, 47(4), 287-296.

39. Veerapu, G., Gangadharappa, H. V., Nagashubha, B., & Balamuralidhara, V. (2014). Review on novel carrier system: liposomes and proliposomes. Drug Delivery Letters, 4(2), 96-109.

40. Kurakula, M., & Koteswar Rao, G. S. N. (2020). Moving polyvinyl pyrrolidone electrospun nanofibers and bioprinted scaffolds toward multidisciplinary biomedical applications. European Polymer Journal, 136, 109919. https://doi.org/10.1016/j.eurpolymj.2020.109919

41. Kurakula, M., Naveen, N. R., & Yadav, K. S. (2020). Formulations for Polymer Coatings. Polymers Coatings: Technology and Applications, 415.

42. Alhakamy, N. A., Ahmed, O. A. A., Kurakula, M., Caruso, G., Caraci, F., Asfouri, H. Z., Alfarsi, A., Eid, B. G., Mohamed, A. I., Alruwaili, N. K., Abdulaal, W. H., Fahmy, U. A., Alhadrami, H. A., Eldakhakhny, B. M., & Abdel-Naim, A. B. (2020). Chitosan-based microparticles enhance eflalgic acid’s colon targeting and proapoptotic activity. Pharmaceutics, 12(7), 1–14. https://doi.org/10.3390/pharmaceutics12070652

43. Kurakula, M., & A Ahmed, T. (2016). Co-delivery of atorvastatin nanocrystals in PLGA based in situ gel for anti-hyperlipidemic efficacy. Current Drug Delivery, 13(2), 211-220.

44. Kurakula, M., El-Helw, A. M., Sobahi, T. R., & Abdelaal, M. Y. (2015). Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy. International journal of nanomedicine, 10, 321.

45. Hasnain, M. S., Kiran, V., Kurakula, M., Rao, G. K., Tabish, M., & Nayak, A. K. (2020). Use of alginites for drug delivery in dentistry. In Alginites in Drug Delivery (pp. 387-404). Elsevier. https://doi.org/10.1016/b978-0-12-817640-5.00015-7.

46. Kurakula, M., & Rao, G. S. N. K. (2020). Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition. Journal of Drug Delivery Science and Technology, 60, 102046. https://doi.org/10.1016/j.jddst.2020.102046

47. Kurakula, M., & Raghavendra Naveen, N. (2020). In situ gel loaded with chitosan-coated simvastatin nanoparticles: Promising delivery for effective anti-proliferative activity against tongue carcinoma. Marine Drugs, 18(4), 201. https://doi.org/10.3390/md18040201.

48. Hasnain, M. S., Nayak, A. K., Kurakula, M., & Hoda, M. N. (2020). Alginate nanoparticles in drug delivery. In Alginites in Drug Delivery (pp. 129–152). Elsevier.

https://doi.org/10.1016/b978-0-12-817640-5.00006-6.

49. Kurakula, M., Rao, G. K., Kiran, V., Hasnain, M. S., & Nayak, A. K. (2020). Alginate-based hydrogel systems for drug releasing in wound healing. In Alginites in Drug Delivery (pp. 323–358). Elsevier. https://doi.org/10.1016/b978-0-12-817640-5.00013-3.

50. Naguib, G. H., Hassan, A. H., Al-Hazmi, F., Kurakula, M., Al-Dharrabah, A., Alkhalihi, H. M., Al-Ahdal, A. M., Hamed, M. T., & Pashley, D. H. (2017). Zein based magnesium oxide nanowires: Effect of anionic charge on size, release and stability. Digest Journal of Nanomaterials and Biostructures, 12(3), 741–749.

51. Rao, G. K., Kurakula, M., & Yadav, K. S. (2020). Application of Electrospun Materials in Gene Delivery. Electrop spun Materials and Their Allied Applications, 265-306.https://doi.org/10.1002/9781119655039.ch10

52. Park, T. G., Cohen, S., & Langer, R. S. (1994). U.S. Patent No. 5,330,768. Washington, DC: U.S. Patent and Trademark Office.

53. Naveen, N. R., Gopinath, C., & Kurakula, M. (2020). Okra-thioglycolic acid conjugate-synthesis, characterization, and evaluation as a mucoadhesive polymer. Processes, 8(3), 316. https://doi.org/10.3390/pr8030316

54. Alhakamy, N. A., Fahmy, U. A., Ahmed, O. A. A., Caruso, G., Caraci, F., Asfouri, H. Z., Bahrehb, M. A., Alomary, M. N., Abdulaal, W. H., Okbazghi, S. Z., Abdel-Naim, A. B., Eid, B. G., Aldawsari, H. M., Kurakula, M., & Mohamed, A. I. (2020). Chitosan coated microparticles enhance simvastatin colon targeting and pro-apoptotic activity. Marine Drugs, 18(4), 201. https://doi.org/10.3390/md18040201.

https://doi.org/10.1016/b978-0-12-817640-5.00006-6.
55. Pattewar, S., Kasture, S., Pande, V., & Sharma, S. (2016). Self microemulsifying drug delivery system: A lipid based drug delivery system. International Journal of Pharmaceutical Sciences and Research, 7(2), 443.

56. Asadujjaman, M. D., & Mishuk, A. U. (2013). Novel approaches in lipid based drug delivery systems. Journal of Drug Delivery and Therapeutics, 3(4), 124-130.

57. Bally, M. B., Lim, H., Cullis, P. R., & Mayer, L. D. (1998). Controlling the drug delivery attributes of lipid-based drug formulations. Journal of Liposome Research, 8(3), 299-335.

58. Langer, R. (1993). Polymer-controlled drug delivery systems. Accounts of chemical research, 26(10), 537-542.

59. Liu, Y., & Liu, J. (2020). Leakage and Rupture of lipid Membranes by Charged Polymers and Nanoparticles. Langmuir, 36(3), 810-818.

60. Zalipsky, S., Woodle, M. C., Lasic, D. D., & Martin, F. J. (1995). U.S. Patent No. 5,395,619. Washington, DC: U.S. Patent and Trademark Office.

61. Schultz, H. B., Thomas, N., Rao, S., & Prestidge, C. A. (2018). Supersaturated silica-lipid hybrids (super-SLH): An improved solid-state lipid-based oral drug delivery system with enhanced drug loading. European Journal of Pharmaceutics and Biopharmaceutics, 125, 13-20.

62. Wang, G., Wang, J., Wu, W., Tony To, S. S., Zhao, H., & Wang, J. (2015). Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs. Expert opinion on drug delivery, 12(9), 1475-1499.

63. Aburahma, M. H., & Badr-ElDin, S. M. (2014). Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals. Expert opinion on drug delivery, 11(12), 1865-1883.

64. Adams, D., Gonzalez-Duarte, A., O’Riordan, W.D., Yang, C-C., Ueda, M., Kristen, A.V., Tournev, I., Schmidt, H.H., Coelho, T., Berk, J.L., Lin, K-P., Vita, G., Attarian, S., Planté-Bordeneuve, V., Mezei, M.M., Campistol, J.M., Buades, J., Brannagan, T.H., Kim, B.J., Oh, J., Parman, Y., Sekijima, Y., Hawkins, P.N., Solomon, S.D., Polydefkis, M., Dyck, P.J., Gandhi, P.J., Goyal, S., Chen, J., Strahs, A.L., Nochur, S.V., Sweetser, M.T., Garg, P.P., Vaishnaw, A.K., Gollob, J.A., Suhr, O.B., 2018. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New Engl. J. Med. 379, 11–21.

65. Ahmed, F., Pakunlu, R. I., Brannan, A., Bates, F., Minko, T., & Discher, D. E. (2006). Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. Journal of Controlled Release, 116(2), 150-158.

66. DeVincenzo, J., Cehelsky, J. E., Alvarez, R., Elbashir, S., Harborth, J., Toudjarska, I., & Meyers, R. (2008). Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral research, 77(3), 225-231.

67. Grieser, J., Hetényi, G., Kadas, H., Demarne, F., Janin, V., & Bernkop-Schnürch, A. (2018). Self-emulsifying peptide drug delivery systems: How to make them highly mucus permeating. International Journal of Pharmaceutics, 538(1-2), 159-166.6

68. Siepmann, J., Faham, A., Clas, S. D., Boyd, B. J., Janin, V., Bernkop-Schnürch, A., … & Merkel, O. M. (2019). Lipids and polymers in pharmaceutical technology: Lifelong companions. International journal of pharmaceutics, 558, 128-142.

69. Friesen, D. T., Shanker, R., Crew, M., Smithey, D. T., Curatolo, W. J., & Nightingale, J.A.S. (2008). Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Molecular pharmaceutics, 5(6), 1003-1019.

70. O’Driscoll, C. M., Bernkop-Schnürch, A., Friedl, J. D., Prétat, V., & Jannin, V. (2019). Oral delivery of non-viral nucleic acid-based therapeutics: do we have the guts for this?. European Journal of Pharmaceutical Sciences, 133, 190-204.

71. Zaichik, S., Steinbring, C., Caliskan, C., & Bernkop-Schnürch, A. (2019). Development and in vitro evaluation of a self-emulsifying drug delivery system (SEDDS) for oral vancomycin administration. International journal of pharmaceutics, 554, 125-133.